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Background: Severe hypoglycaemia (SH) is one of the most feared complications of type 1 diabetes (T1DM) with a
reported prevalence of nearly 40%. In randomized trials of Multiple Daily Injections (MDI) and Continuous
Subcutaneous Insulin Infusion (CSII) therapy there is a possible benefit of CSII in reducing SH. However few trials
have used basal insulin analogues as the basal insulin in the MDI group and individuals with established SH have
often been excluded from prospective studies. In published studies investigating the effect of Real Time Continuous
Glucose Monitoring (RT-CGM) benefit in terms of reduced SH has not yet been demonstrated. The primary
objective of this study is to elucidate whether in people with T1DM complicated by impaired awareness of
hypoglycaemia (IAH), rigorous prevention of biochemical hypoglycaemia using optimized existing self-management
technology and educational support will restore awareness and reduce risk of recurrent SH.
Methods/design: This is a multicentre prospective RCT comparing hypoglycaemia avoidance with optimized MDI
and CSII with or without RT-CGM in a 2×2 factorial design in people with type 1 diabetes who have IAH. The primary
outcome measure for this study is the difference in IAH (Gold score) at 24 weeks. Secondary outcomes include
biomedical measures such as HbA1c, SH incidence, blinded CGM analysis, self monitored blood glucose (SMBG) and
response to hypoglycaemia in gold standard clamp studies. Psychosocial measures including well-being and quality of
life will also be assessed using several validated and novel measures. Analysis will be on an intention-to-treat basis.
Discussion: Most existing RCTs using this study’s interventions have been powered for change in HbA1c rather than
IAH or SH. This trial will demonstrate whether IAH can be reversed and SH prevented in people with T1DM in even
those at highest risk by using optimized conventional management and existing technology.
Trial Registration: ISRCTN52164803 Eudract No: 2009-015396-27Background
Type 1 diabetes mellitus (T1DM) accounts for 5–10%
[1] of those with diabetes and is characterised by an ab-
solute deficiency of insulin caused by immunologically
mediated damage to the beta-cells in the pancreas.
Onset can occur at any age but is most commonly in
children, adolescents and young adults. Complications* Correspondence: jim.shaw@ncl.ac.uk
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reproduction in any medium, provided the orinclude microvascular disease of the kidneys, eyes and
nervous tissue in addition to macrovasular disease such
as ischaemic heart disease, cerebrovascular disease and
peripheral vascular disease.
As there is no cure for T1DM, management entails
regulation of blood glucose levels with insulin replace-
ment therapy and dietary modification. There is incon-
trovertible evidence from the landmark DCCT [2] and
the follow-up EDIC [3] study that microvascular and
macrovascular complications can be prevented by rigor-
ous avoidance of high glucose levels.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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placement therapy, however, severe hypoglycaemia (SH)
remains the major factor limiting optimal glycaemic con-
trol [4]. In a retrospective epidemiological survey of an
unselected population with T1DM the prevalence of SH
was reported to be 37% over a one year recall period [5].
SH remains one of the most feared complications of insu-
lin therapy as it can result in collapse without warning,
fits, or even sudden death [6,7]. Tight glycaemic control in
the DCCT attained by MDI (multiple daily injections) or
CSII (continuous subcutaneous insulin infusion) was asso-
ciated with a three-fold increase in SH [2].
Established risk factors for SH include age, duration of
diabetes, tight glycaemic control, previous SH and impaired
awareness of hypoglycaemia (IAH) [8]. IAH occurs in 20%
of those with T1DM and is characterised by diminished
autonomic warning symptoms of impending hypoglycaemia
and associated with a six-fold increased risk of SH [9-11].
Antecedent biochemical hypoglycaemia (BH) including si-
lent nocturnal hypoglycaemia can induce IAH in addition
to diminished counter-regulatory hormone response in
people with established diabetes [12].
In insulinoma patients, surgical resection restores
normal symptomatic and neuroendocrine response to
hypoglycaemia providing further evidence of the direct
causative role of BH in IAH and SH [13]. Rigorous
avoidance of hypoglycaemia by relaxing glycaemic tar-
gets while maintaining conventional MDI therapy has
been shown to restore hypoglycaemia awareness with
normalisation of glycaemic thresholds for symptoms
and neuroendocrine responses during a stepped hyper-
insulinemic–hypoglycaemic clamp study [14,15]. This
was, however, associated with a 0.4–1.1% (4–12 mmol/
mol) increase in HbA1c. Moreover, success has previ-
ously been confined to those with relatively short dur-
ation of diabetes [7] or transiently following a brief
period of absolute hypoglycaemia avoidance in those
with longer duration diabetes [8].
The potential for reducing nocturnal and late post-
prandial hypoglycaemia by employing rapid-acting insulin
analogues pre-prandially has been demonstrated [16-18].
In addition, reduced nocturnal hypoglycaemia has been
reported in insulin glargine trials [19-23] and insulin dete-
mir trials [24-27]. However, individuals with a previous his-
tory of IAH and SH and longer duration of diabetes have
typically been excluded from randomized clinical trials in-
vestigating insulin analogues. The National Institute for
Health and Clinical Excellence (NICE) in the UK has
recommended further studies to assess the impact of insu-
lin analogues on duration and severity of hypoglycaemia
and on quality of life (QoL) [28].
In randomized trials of CSII versus MDI, a relatively
modest improvement in HbA1c has been demonstrated
in addition to the potential for reduction in theincidence of SH [29,30]. There have been relatively few
trials to date with glargine as the basal insulin in the
MDI comparator group [30,31]. A Cochrane review has
indicated a possible benefit of CSII as compared to MDI
in reducing SH but data also indicated no benefit of CSII
in reducing non-severe hypoglycaemic events [32]. Indivi-
duals with established SH have again often been excluded
from prospective studies, despite a reported sustained re-
duction in the incidence of SH in a non-randomized,
retrospective study [33]. NICE recommends CSII therapy
where achievement of optimal glycaemic control has been
precluded by disabling hypoglycaemia but has emphasized
the absence of studies in high-risk individuals together
with the need for randomized control trials to assess bio-
medical and psychosocial outcomes of both analogue
MDI and CSII in those with established SH [34].
The potential role of real time continuous glucose mon-
itoring (RT-CGM) has generated considerable interest
among clinicians and those with T1DM since its introduc-
tion. Improved overall glycaemic control has been
reported, though benefit in terms of reduced SH has not
yet been demonstrated [35,36]. Studies that have com-
pared RT-CGM integrated with CSII with analogue regi-
mens have also failed to demonstrate a difference in rates
of SH although they have suggested reduced HbA1c with
the technology [37,38]. There is evidence that RT-CGM
can significantly reduce the time spent with a blood glu-
cose <3.5 mmol/l [39], however there is no evidence from
the major RCTs published that it can prevent SH. This
may be due to the study design and participant selection
criteria of these trials. Sustained avoidance of BH achieved
through feedback from RT-CGM use with the aim of re-
storing hypoglycaemia awareness and preventing risk of
further SH in high-risk individuals with T1DM has not
been assessed.
Despite implicit acknowledgement amongst healthcare
professionals that SH impairs an individual’s QoL, there
is little formal evidence for this in the literature. Davis
et al., have demonstrated the major impact of SH on per-
ceived health and well being [40] but the full impact of
SH on QoL has not been assessed adequately. Relatively
few studies have directly assessed impact of successful
prevention of further SH in addition to differential effects
according to therapeutic intervention.
We have previously conducted a 6-month randomised
prospective pilot study in individuals with T1DM compli-
cated by SH, comparing rigorous BH avoidance with opti-
mised analogue MDI; CSII; or education alone (EDUC)
[41]. This demonstrated absolute prevention of recurrent
SH in 71% in all groups. Quantitative improvement in
IAH was confirmed using the validated Clarke question-
naire [42] in addition to restored symptomatic response to
clamp-induced hypoglycaemia. Concomitant improvement
in glycaemic control (HbA1c) was achieved with MDI
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CSII (baseline: 8.5 ± 1.9%, endpoint: 7.4 ± 1.0%, p = 0.06)
but not EDUC (baseline: 8.5 ± 1.1%, endpoint: 8.3 ± 1.0%,
p = 0.54). Significant improvements in diabetes-specific
QoL and fear of hypoglycaemia were also demonstrated in
MDI and CSII groups. Although in this study RT-CGM
was not used, these pilot data provide the rationale,
robust power calculation and proven study design for a
definitive RCT, without the requirement for an educa-
tion alone arm.
Study objectives
Primary objective
 To demonstrate that by optimising conventional
management, including the use of real time
continuous glucose monitoring (RT-CGM), in
individuals with T1DM complicated by IAH,
rigorous prevention of BH will restore awareness
and reduce risk of recurrent SH.
Secondary objectives
 To quantify and compare BH identified by self-
monitored blood glucose (SMBG) and blinded CGM
profiles during each intervention.
 To quantify and compare overall glycaemic control
and glucose lability in each group by analysis of
HbA1c, SMBG and blinded CGM.
 To quantify and compare total daily doses of insulin
before and after the intervention period.
 To compare health utility, well-being and QoL during
each intervention using validated and novel measures.
 To perform secondary analyses of those who continue
to experience IAH regardless of study intervention, to
determine factors associated with absence of
response. It is hypothesised that these will include two
sub-groups: one in whom an absolute focus on
avoidance of high glucose (evidenced from patient-
reported outcome (PRO) measures) leads to
continued biochemical hypoglycaemia despite the
study goals; and a second with severe autonomic
neuropathy (evidenced from clinical history) who are
unable to recover autonomic warning symptoms of
hypoglycaemia despite effective reduction in
biochemical hypoglycaemia.
 To determine symptomatic, counter-regulatory
hormone and cognitive response to hypoglycaemia in
gold standard clamp studies. Comparisons will be
made between those randomised to CSII and those
randomised to MDI; in addition to RT-CGM versus
no RT-CGM; and responders with restored
hypoglycaemia awareness versus non-responders with
persistent IAH despite study intervention.Methods/design
Ethical and governance approval
Ethical approval for this study has been granted by Sun-
derland Research Ethics Committee (09/H0904/63) and
Clinical Trial Authorisation has been given by the Medi-
cines and Healthcare products Regulatory Agency
(17136/0246/001-0001). Site Specific Approval has been
granted by all participating Acute Hospital Trust Re-
search and Development Departments.
Study design
The study is an interventional multicentre prospective
RCT comparing hypoglycaemia avoidance with optimised
subcutaneous insulin analogue regimen (MDI) and insulin
pump therapy (CSII) with or without adjunctive RT-CGM
in a 2×2 factorial design (Figure 1). The trial design is
consistent with the CONSORT Statement [43].
Participants
Participants will be recruited from the diabetes clinics of
the five participating UK tertiary referral and academic
hypoglycaemia/CSII centres (Royal Bournemouth Hos-
pital, Bournemouth; Addenbrooke’s Hospital, Cambridge;
Newcastle Diabetes Centre, Newcastle upon Tyne, UK;
Derriford Hospital, Plymouth; Northern General Hospital,
Sheffield). Patients with T1DM, a history of IAH and
increased risk of SH will be assessed to determine if they
are eligible for the study. It is envisaged that the majority
of these will have experienced SH within the preceding
year, although this is not mandatory for study participa-
tion. Those who are considered potentially eligible will be
approached to give their written informed consent before
attending for a screening visit at which inclusion criteria
will be checked.
Inclusion criteria
Individuals who are aged 18–74 years and have a diagnosis
of diabetes mellitus according to ADA [44] / WHO [45]
criteria and consistent with a clinical diagnosis of T1DM.
Participants will have:
 serum C-peptide below the quality assured limit of
detection for the assay and laboratory (<50 pmol/L)
with simultaneous exclusion of BH (glucose
<4.0 mmol/l) by laboratory plasma glucose assay.
 impaired awareness of hypoglycaemia, as confirmed
by a Gold score ≥4 [11].
Exclusion criteria
 Any condition that in the investigator’s judgement is
likely to cause the participant to be unable to
understand the information in the Informed
Consent Document or to provide informed consent.
CSII: Continuous Subcutaneous Insulin Infusion
MDI: Multiple Daily Injections
RT-CGM: Real-Time Continuous Glucose Monitoring
Withdrawn (n=...)
Lost to follow up (n=...)
Excluded (n=...)
Withdrew from study 
pre randomisation 
(n=...)
Did not meet inclusion 
criteria following 
serum C-peptide 
analysis (n=...)
Patient Recruitment & consent 
target (n=100)
Participants randomised after a 
4-week wash-in period (n=...)
MDI arm (n=50) CSII arm (n=50)
CSII (n=25) CSII & RT-CGM
(n=25)
MDI (n=25) MDI & RT-CGM
(n=25)
Analysed (n=...)
Figure 1 Proposed flow through RCT.
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enable the participant to understand both verbal and
written information during the study. This is due to
the complexity of the education programme, the
need for independent completion of the
questionnaire measures, and the degree of
communication required between participants and
clinicians during the study.
 Unwilling to undertake intensive insulin therapy,
including randomisation to use of CSII, optimised
MDI regimen or RT-CGM.
 Unwilling to undertake glucose profiles using the
subcutaneous continuous glucose monitoring
(CGM) equipment.
 Unwilling to use SMBG at least 4 times daily. Unwilling to monitor and record signs and
symptoms of hypoglycaemia.
 A history of intolerance to insulin glargine.
Trial intervention and study procedures
Schedule for study visits is given in Table 1.
Four week baseline period
After consent, participants will undertake a 4-week wash-
in period before the 24-week RCT period. Participants will
be educated in the use of the study-specific prospective
SMBG hypoglycaemia diary. All participants will be pro-
vided with a study hand-held glucometer (Contour linkW,
Bayer Healthcare) to measure daily 4-point and weekly
8-point profiles. They will be asked to record clinical
Table 1 Visit schedule
Study period 4 week
wash in
period
24 week primary RCT 18 month RT-CGM RCT
continuation
Visit number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
informed consent x
eligibility criteria x
given information sheet on clamp
study
x x
hypoglycaemia screening
questionnaire
x x
HbA1c x x x x x x x x x x x
C-peptide and plasma glucose x
retinal photographs x
urine albumin:creatinine ratio x
demographic info x
concomitant medication x x x x x x x x x x
full physical examination x x
history of glycaemic control x x x x x
full medical history including
glycaemic control
x x x x x
vital signs x x x x x x x x x x
height x
weight x x x x x x x x x x
TFTs x
Coeliac antibody x
short synacthen test x
detailed SH history x x x x x x x x x x
Modified Clarke/Edinburgh x x x x x
QoL questionnaires x x x x x
week 4 short questionnaire pack x
4 week Blood Glucose / hypo diary x x x x x x x x
7 day CGMS placement x x x x x x x x x x
Autonomic function tests x x
clamp study x x
education programme x
Insulin administration education
session
x
Home glucose monitoring/RT
education session
x
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hypoglycaemic events. All participants will wear a blinded
CGM device (iPro™ 1, Medtronic) for 7 days during the
baseline period.
At the end of the wash-in period, participants will at-
tend for a baseline study visit where the investigator will
complete the GCP-compliant baseline Case Report Form
(CRF). This will record demographic information, full
diabetes-specific clinical history including frequency andconsequences of SH events over the preceding 12 months
and full clinical examination assessing complication status.
The study SMBG / hypoglycaemia diary will be collected
and CGM device downloaded. In addition, hypoglycaemia
awareness will be re-evaluated using the validated Gold
Score [11] and Clarke questionnaire [42].
A first morning urine sample for albumin: creatinine
ratio will be collected together with dilated retinal photog-
raphy if not performed within the preceding 6 months. A
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urea and electrolytes, liver function tests and lipid profile
analysed at local site quality-assured clinical laboratory.
Study-specific PRO questionnaire booklets will be com-
pleted comprising several validated and novel measures.
During design of and preparation for the study, new mea-
sures were developed by the team to capture aspects of
participant experience for which validated measures did
not exist (e.g. hypoglycaemia cues) or where there was
specific concern that existing measures were insensitive
(e.g. the Gold and the Clarke have been demonstrated to
lack sensitivity to improvements in awareness). All PRO
measures included in the evaluation are listed in Table 2.Baseline hypoglycaemic clamp study
A stepped hyperinsulinaemic hypoglycaemic clamp study
will be conducted at baseline and at 24 weeks with partici-
pants who are willing to undergo this procedure for which
specific consent will be sought separately. It is envisaged
that approximately 25% of participants will be studied.
The method is described in detail later.Autonomic function testing
Before the start of the RCT, participants will attend for
non-invasive detailed cardiac autonomic function testing
using the recommendations in the review by Tesfaye
et al. [46]. These will include heart rate response to deep
breathing, a Valsalva maneuver and heart rate and blood
pressure response to standing interpreted using age nor-
mative values. Spectral analysis of heart rate variability
and assessment of cardiac vagal baroreflex sensitivity
(BRS) will be carried out over a five minute period of
controlled breathing. Structured assessment of global
autonomic function will be made using the Autonomic
Symptom Profile Questionnaire [47].Table 2 Validated and novel patient reported outcome measu
Validated PRO measures
• The Gold Score [44]
• The Edinburgh Hypoglycaemia Survey [54]
• Clarke Hypoglycaemia Awareness Questionnaire (minimally modified versio
• The Hypoglycaemia Fear Survey II (HFS II) [55]
• The Hyperglycaemia Avoidance Scale [56]
• The Diabetes Treatment Satisfaction Questionnaire – status version (DTSQ(s
• Insulin Treatment Satisfaction Questionnaire [58] – abridged version includi
subscales only
• EuroQoL EQ-5D [59]
• Perceived Control of Diabetes scales (type 1) [60]
* designed by Prof Jane Speight and Dr Shalleen Barendse (© AHP Research, 2010).
^ designed by Prof Jane Speight, Dr Alison Woodcock and Matthew Reaney (© AHP
# designed by Dr Nicole DeSoyza, Helen Rogers and Prof Stephanie Amiel (King’s CConcomitant autoimmune disease screening
Participants will attend for a short synacthen test to screen
for adrenocortical insufficiency. At this visit a sample will
also be taken for serum thyroid stimulating hormone assay
to exclude thyroid disease and for anti-endomysial anti-
body analysis to exclude coeliac disease. New diagnoses of
other autoimmune diseases will not preclude participation
in the study. If indicated participants with newly diag-
nosed autoimmune disease will be referred to an appropri-
ate specialist for further investigation and management.Education visit
Following experience in the pilot study [41] and informed
by insights from the qualitative study undertaken in prep-
aration for the RCT (paper submitted), a brief education
programme (with formal curriculum and workbook, re-
ferred to as the ‘My Hypo COMPaSS’ tool), was devel-
oped. Participants will attend a brief education session
(approximately 3 h) individually or in small groups of up
to four. During the session, a trained research fellow, spe-
cialist nurse or dietician will facilitate discussions and
exercises targeted specifically at rigorous avoidance of BH
while maintaining overall glycaemic control [48], includ-
ing four key elements forming the four points of the
‘Hypo COMPaSS’ establishing the imperatives: to never
delay the treatment of hypoglycaemia and the optimal
treatments for hypoglycaemia; to recognise the indivi-
dual’s unique times of increased risk; to recognise
hypoglycaemia by the presence of subtle symptoms; to be
particularly careful about detecting and preventing noc-
turnal hypoglycaemia. Also included will be advice on
self-adjustment of insulin doses according to carbohy-
drate intake, SMBG and planned activity and recommen-
dation for oral carbohydrate administration for all glucose
levels less than 4 mmol/l.res assessed during the Hypo COMPaSS trial
Novel PRO measures undergoing validation
• The Hypoglycaemia Awareness Questionnaire (HypoA-Q)*
• The Hypoglycaemia Burden Questionnaire (HypoB-Q)* –
part A only
n)
• The Hypoglycaemia Cues Questionnaires (HypoC-Q)*
• The Blood Glucose Monitoring Questionnaire (BGM-Q)*
)) [57] • The Quality of Life Questionnaire Diabetes (QoL-Q
Diabetes)^
ng two • The Attitudes to Awareness of Hypos Questionnaire#
Research, 2007).
ollege London).
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Randomisation
Participants will be allocated by third party concealed
randomisation by centre and baseline HbA1c (with
stratification cut-off of 64 mmol/mol (8%) to one of four
groups for a period of 24 weeks):
 MDI with SMBG (group 1; n = 25).
 MDI with SMBG and RT-CGM (group 2; n = 25).
 CSII with SMBG (group 3; n = 25).
 CSII with SMBG and RT-CGM (group 4; n = 25).
As this is an open study it is not possible for partici-
pants to be blinded to study treatment arm. Randomisa-
tion will be administered centrally by Newcastle Clinical
Trial Unit (NCTU) using a secure web based system.
Study Interventions
The primary goal of titration throughout the 24-week
RCT period will be the absolute avoidance of all glucose
levels <4 mmol/l as determined by CGM and SMBG.
This will be achieved by setting ‘4 as the floor’ with all
glucose levels <4 mmol/l treated by 15 g glucose with re-
peat SMBG every 15 min until glucose >4 mmol/l, in
addition to consideration of insulin dose reduction.
The trial is designed to prevent any potential bias from
additional educational support provided to those rando-
mised to CSII or RT-CGM. All participants will be pro-
vided with a Medtronic Veo insulin pump to enable use
of the bolus prandial insulin dose wizard calculator
whether or not they are administering insulin by CSII.
All will be provided with a Contour link SMBG meter
enabling direct transmission to the pump dose calcula-
tor. Access to Carelink glucose self-management soft-
ware will also be provided to all participants to be used
optionally to support attainment of study targets without
any specific additional goals / training.
All participants (regardless of treatment arm) will
attend an education session solely on the technical
aspects of the insulin administration or glucose monitor-
ing equipment they will be using during the intervention
period, i.e. participants randomised to CSII will receive
education restricted to technical aspects of insulin pump
management including on the need to change the infu-
sion set at least every 72 h; participants randomised to
MDI will receive education restricted to insulin device
(pen) use and injection site care.
Participants randomised to RT-CGM will receive edu-
cation restricted to the technical aspects of using the
RT monitors including trend analysis and the use of
the hypoglycaemia and hyperglycaemia alarms. They
will be encouraged to wear the sensor continuously
(re-siting every 7 days) but flexibly with a minimum of
7 days continuous monitoring in the last week of eachmonth. Participants not randomised to RT-CGM will
receive education restricted to the technical aspects of
using the Contour link meter with the bolus calculator
on the pump.
Participants will be seen one week after starting the
study intervention to review progress over the first week,
using glucose data to achieve the primary goal of avoid-
ing biochemical hypoglycaemia.
Study drugs and devices
In accordance with the Medicines for Human Use (Clinical
Trials) Regulations 2004 and Directive 2001/20/EC, the
drugs under investigation in this trial fall under the
definition of ‘investigational medicinal product’ (IMP).
Although the insulins used during this trial fall under
the definition of IMPs they will be used under existing
licence.
Insulin for MDI participants
For the participants randomised to MDI, insulin aspart
will be given as 3 ml cartridge 100 Units/mL in a pre-
filled pen (FlexpenW). Insulin glargine will be given as 3 ml
cartridge 100 Units/mL in a pre-filled pen (SoloStarW).
However, for those participants who have had a previous
negative experience or adverse effect with insulin aspart, in-
sulin lispro will be offered as 3 ml cartridge 100 Units/mL
in a pre-filled pen (KwikpenW).
Insulin for CSII participants
For participants randomised to CSII, insulin aspart will be
the insulin used as 10 ml vial 100 Units/mL. Insulin lispro
can be used instead of insulin aspart for those who have
had previous negative experience / adverse effects.
Insulin pumps
All participants will be given an insulin pump that can
receive and display CGM data (Mini-Med Paradigm Veo
insulin pump) and will be taught how to use the on-
board bolus calculator. Only those randomised to CSII
will use the pump for insulin administration, the MDI
groups will only use the bolus calculator feature and, if
randomised to RT-CGM, the CGM feature. All partici-
pants randomised to CSII (insulin pump therapy) will be
given a single additional session restricted to technical
aspects of pump management.
Self Monitoring of Blood Glucose (SMBG)
All participants will be required to undertake daily 4-
point and weekly 8-point self-monitored capillary glu-
cose profiles. All participants will use the Contour linkW,
Bayer Healthcare meter and will undertake this whether
or not concurrent RT-CGM is being used.
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Fifty per cent of all participants will be randomised to
real time monitoring, using the CE-marked REAL time
continuous glucose monitor (Medtronic).
Advice on interpretation and action from SMBG / RTCGM
All participants will attend an education session on the
recording of SMBG but, for those participants rando-
mised to RT-CGM, this session will also include the
technical aspects of using the monitor. This includes
trend analysis, hypoglycaemia and hyperglycaemia alarms.
Participants will be given written instructions on how to
use the data provided by continuous glucose monitors to
make real-time adjustments of insulin doses and on the
use of computer software (for those with a home com-
puter) to retrospectively review the glucose data to alter
future insulin doses. Participants randomised to RT-CGM
will be encouraged to wear the sensor continuously but
flexibly with a minimum of 7 days continuous monitoring
in the final week of each month. Those participants ran-
domised to RT-CGM will be advised to re-site the sensor
every 7 days.
Blinded continuous glucose monitors
Blinded CGM will be undertaken using the CE-marked
Medtronic wireless iPro system. These will be used in
the 4-week wash in period and during the last seven
days of every month. The patients and investigators are
blinded to all of this data until the end of the primary
24 week RCT.
Insulin titration protocol
The blood glucose targets (for all patients in CSII and
MDI groups) will be as follows:
Fasting blood glucose (FBG): 5.0 - 7.0 mmol/l.
Pre-prandial blood glucose: 4.5 - 7.0 mmol/l.
Post-prandial glucose*: 6.0 – 8.0 mmol/l.
Bedtime blood glucose**: 6.0 – 8.0 mmol/l.
4 am blood glucose: 5.0 – 7.0 mmol/l.
*postprandial blood glucose: measurement made 2 h
after the start of a meal.
**bedtime blood glucose: measurement made within
30 min of retiring to bed for the night.
Glargine titration in MDI group
Insulin glargine will be self-administered and the follow-
ing titration protocol will be followed:
 Take within 30 min of retiring to bed for night / no
need for snack.
 Aim for stable (not falling) glucose through the
night. Reduce dose if any hypoglycaemic episodes or
glucose <5.0 mmol/l between 4 am and before
breakfast.
 Target glucose of 5–7 mmol/l before breakfast—
adjust dose by 1–2 units to maintain target if
necessary with primary aim being absolute
avoidance of BH (Biochemical Hypoglycaemia).
 During periods of illness, basal insulin doses may need
to be altered and this will be guided by SMBG levels.
Introduction of twice daily glargine
Participants randomised to MDI already on twice daily
glargine will continue on this from the outset of the
RCT. In other MDI participants, if glucose is consist-
ently >7 mmol/l before evening meal or highly variable
between breakfast and evening meal, add second dose of
insulin glargine before breakfast. Initial dose will be 4
units but can be adjusted in light of participant’s current
insulin doses. If glucose has been falling through the
night, a 2–4 unit reduction in evening glargine dose will
be actioned before bed on the day of commencing the
morning dose. The addition of a second daily glargine
dose will be considered for all participants in the MDI
group. This can be initiated between study visits if ne-
cessary, e.g. after telephone advice.
Morning insulin glargine will be self-administered and
adjusted as follows:
 Take within 30 min of rising from bed for the
morning.
 Aim for stable (not falling) glucose through the
afternoon.
 Reduce dose if any hypoglycaemic episodes or
glucose <5 mmol/l between 2 h after lunch and
evening meal.
 Target glucose of 5-7 mmol/l before evening meal –
adjust dose by 1–2 units to maintain target if
necessary with primary aim being absolute
avoidance of BH.
Basal insulin titration in CSII group
The basal insulin delivery rate will be titrated according
to fasting, bedtime, pre-prandial and 4 am glucose levels
ensuring absence of recurrent low glucose levels at these
times (checkpoints). Increased or decreased delivery will
be commenced from the previous basal insulin check-
point level, i.e. if low at 4 am—decrease from bedtime; if
high fasting increase from 4 am.
Mean fasting; bedtime; 4 am and pre-prandial blood
glucose:
 Within target: No change to basal delivery rate.
 Above target: Increase basal insulin by 0.1 U/hr
from previous check point.
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hypoglycaemia: Decrease basal insulin by 0.1 U/hr
from previous check point.
During periods of illness, basal insulin rates may need
to be altered and this will be guided by SMBG levels.Meal-time insulin bolus in all groups (CSII and MDI)
Carbohydrate counting skills and bolus dose adjustment
in light of current blood glucose level / individualised in-
sulin carbohydrate ratios will be reviewed in all partici-
pants. Aspart or lispro will be delivered either by
subcutaneous injection or as a subcutaneous pump
bolus before all meals and snacks with substantial carbo-
hydrate content.
Insulin: carbohydrate ratios will be calculated for all
individuals using the ‘500 rule’ and using total daily insu-
lin doses pre-randomisation. The ‘500 rule’ is:
500 divided by the TDD (Total Daily Dose of insulin) =
grams of carbohydrate covered by one unit of aspart or
lispro.
In the event of high pre-prandial glucose levels cor-
rective doses will also be recommended with meals as
part of the meal time bolus. This will be calculated using
the ‘100 rule’ for estimation of Insulin Sensitivity Factor.
The ‘100 rule’ is:
100 divided by the TDD (Total daily Dose of insulin) =
glucose drop in mmol/l per 1 unit of aspart or lispro.
This will be presented to all participants as ‘1 unit of
aspart / lispro will reduce your blood glucose by x mmol/l’.
Corrective doses with all pre-main meal boluses /
prandial insulin injections will be encouraged according
to the 100 rule when glucose level is above target.
The insulin: carbohydrate ratio and Insulin Sensitivity
Factor for that period of the day will be adjusted accord-
ingly in the event that:
 The glucose level is consistently below or above
target 2 h after a bolus / prandial insulin injection.
 If any unexplained hypoglycaemic event occurs 2 h
after a bolus / prandial insulin injection.Telephone contact
Participants will be contacted by telephone daily for the
first week after starting the study intervention and there-
after weekly throughout the RCT to reinforce the primary
goal of BH avoidance, provide clinical review / support,
and ensure diary completion.Study follow up
Participants will attend for a study visit every four weeks
during the RCT for collection of SMBG/hypoglycaemia
diary and HbA1c. One week prior to each visit partici-
pants will have a blinded CGM device fitted and these
data will be downloaded at the visit. Participants will
have their weight measured at each follow up visit and
this, along with details of insulin dosage, will be
recorded on visit specific CRFs. Both investigator and
participant will remain blinded to the results of the
blinded CGM data during the RCT period. Clinical re-
view at each follow up visit will reinforce the primary
goal of BH avoidance. At each follow up visit informa-
tion will be collected on any episodes of hypoglycaemia
experienced, duration of RT-CGM monitoring usage and
RT-CGM alarm settings.
At week 24, participants will attend for the primary
RCT completion visit. This will include blinded CGMS
data download, collection of SMBG/hypoglycaemia
diary, and HbA1c. Participants will also be asked to
complete the ‘end of RCT’ study-specific questionnaire
booklets assessing hypoglycaemia experience and other
PROs (Table 2).
On the same day, participants will be invited to attend
for ‘end of RCT’ stepped hyperinsulinaemic hypoglycaemic
clamp as described below.
At the end of this intervention period, participants will
be asked to attend for repeat detailed cardiac autonomic
function testing and subjective assessment of global
autonomic symptoms.Post primary RCT follow-up
At the end of the 24-week RCT, participants will return to
routine clinical care. Those randomised to CSII may stop
this if they and their clinical team wish. Commencement
of CSII according to NICE guidance [34] will be consid-
ered in those previously randomised to MDI. Those parti-
cipants who were randomised to RT-CGM will continue
with this intervention for a further 18 months constituting
an overall 24 month RCT of RT-CGM augmented glucose
monitoring vs SMBG alone. RT-CGM will not be offered
to those not randomised to this intervention, as it is not
currently recommended by NICE. All participants will be
invited to attend three follow-up visits 6, 12 and 18 months
post primary RCT (Table 1). Participants will be fitted
with a blinded CGM device for 7 days before each follow-
up visit. This visit will include collection of SMBG/
hypoglycaemia diary; SMBG / CGM data download, HbA1c
measurement. Participants will be required to complete
questionnaire booklets (Table 2) at each follow-up visit.
The end of the study will be the last follow-up visit of
the last participant scheduled for 24 months after the
commencement of study interventions.
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A stepped hyperinsulinaemic hypoglycaemic clamp study
[49] will be conducted in participants who are willing to
undergo this procedure for which separate informed con-
sent will be obtained. It is envisaged that approximately
25% of participants will be studied. Additional exclusion
criteria will be in place to ensure participant safety:
 Age >60 years.
 History of epilepsy (seizures not primarily induced
by hypoglycaemia).
 Known ischaemic heart disease.
 Other significant disease which in the judgement of
the investigator precludes participation.
Participants will be fitted with a retrospective CGM
sensor to be worn typically for five to seven days (at least
24 h) preceding the study day. This will be downloaded
on the morning of the study to determine whether any
antecedent biochemical hypoglycaemia (BH) occurred
over the 24 h period prior to the clamp. Studies will be
postponed to another day if any CGM and/or self-
monitored capillary glucose below 3.0 mmol/l are detected
during the preceding 24 h. For participants who required
rescheduling, a further 72 h of CGM will be organised. All
participants will be advised to fast from 22:00 h and to
avoid caffeine for 24 h before the study.
The participant will be admitted to the clinical re-
search facility at 7 am on the day of the study. On ar-
rival, an intravenous cannula will be inserted in the
ante-cubital vein of the non-dominant arm and blood
glucose will be stabilized using sliding scale insulin infu-
sion aiming initially for blood glucose 6.0–7.0 mmol/l
and then 5.0–6.0 mmol/l between 10.30 am and 11 am
for clamp initiation.
A second retrograde cannula will be inserted into a vein
on the dorsum of the non-dominant hand for the sam-
pling of arterialised venous blood. The hand will be kept
in a purpose-built heated box (Temp 50–60°Celsius)
before inserting the retrograde cannula and throughout
the clamp study. A slow intravenous infusion of saline
will be used as needed to keep the sampling line patent.
During this period of stabilization, participants will be
shown how to perform specific cognitive function tests
(Four choice reaction time [50-52] and Stroop tests
[53,54]) and asked to practise the tests until they achieve
consistent results (typically 5 practice sessions). Four-
choice reaction time is a test of attention, discrimination
and motor speed reaction while Stroop tests are a group
of related sub-tests all requiring selective attention and
mental tracking.
At the start of the clamp a primed infusion of 60 mU/
m2/min soluble human Actrapid insulin will be started
via the non-dominant antecubital vein catheter. Dextroseinfusion rates will be adjusted as needed, aiming to stabil-
ise plasma glucose at 5.0 mmol/l at 40mins followed by
step-wise lowering to 3.8 mmol/l, 3.4 mmol/l 2.8 mmol/l
and 2.4 mmol/l. Each step will last 40 min allowing
20 min to achieve new target and 20 min for stabilization
at that level. Samples for plasma glucose will be obtained
every 5 min and analysed in real-time but participants will
be blinded to these glucose levels throughout the study.
At the end of each clamp stage participants will be
asked to complete a validated symptom questionnaire
[55,56] followed by the four choice reaction time test
and Stroop test. Each symptom will be graded on a vis-
ual analogue scale from 1 (not at all) to 7 (very severe).
Arterialised venous blood samples for insulin, catecho-
lamines, growth hormones, glucagon and cortisol will be
obtained every 10 min during the first 40 min of the
study (euglycaemia) followed by every 20 min during
progressive hypoglycaemia. Heart rate and blood pres-
sure will be recorded every 20 min. In addition, spectral
analysis of heart rate variability and assessment of car-
diac vagal baroreflex sensitivity (BRS) will be carried out
during each clamp stage. At the end of the study, insulin
infusion will be reduced to basal insulin requirements
and dextrose infusion increased to raise blood glucose to
euglycaemia. Participants will be provided with lunch
with post-meal insulin bolus and re-established on their
usual insulin regimen thereafter.
Sample size
The recruitment target for the overall RCT is n = 100
participants (n = 20 from each of the five participating
centres). From the pilot study data [41], the sample size
of n = 100 (n = 25 in each of the four study arms) would
give 80% power at a significance level of 0.05 to detect a
difference of 1.1 between the IAH scores (assessed using
the Gold Score) of the 50 participants randomised to ei-
ther of the CSII arms and the 50 randomised to either of
the MDI arms. A difference of at least one point (on the
7-point scale) is considered to be a clinically relevant
change on the Gold Score. The calculation is based on
the use of the 2-sample t-test and the assumption, taken
from the pilot data, that the standard deviation of the
IAH score is 2 (mean ± SD Gold Score in the pilot study
was 2.57 ± 1.90 in the CSII arm and 4.0 ± 1.79 in the
MDI arm).
Outcomes / statistical analysis
The principal analysis will examine the factorial struc-
ture of the treatment and monitoring regimen effects on
the difference in IAH (Gold score) at 24 weeks using
analysis of covariance (ANCOVA). Baseline IAH (Gold
score) and stratification (centre and baseline HbA1c)
variables will be included among the covariates to be
considered in addition to suitable summaries of
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lected at baseline prior to randomisation. The glucose
monitoring data to be collected include time spent for
the following separate ranges: <2.5 mmol/l, <3 mmol/l,
<4 mmol/l, >7 mmol/l, >10 mmol/l, between 4 and
7 mmol/l and between 3 and 10 mmol/l. The inclusion
of baseline HbA1c as a covariate will enable the exam-
ination of possible interactions between effects observed
and these values.
Further analyses will be undertaken concerning IAH to
corroborate the Gold Score; the Gold Score will be com-
pared with scale and subscale scores derived from the
Clarke Questionnaire and the Hypoglycaemia Awareness
Questionnaire (HypoA-Q) at 24 weeks.
These measures will also be subject to analysis as for
the primary outcome. Additionally, a binary indicator
of IAH response (defined as a Gold Score of <4 or ≥4)
at 24 weeks will be analysed using logistic regression
making use of the covariates used for the primary out-
come analysis.
There will also be an additional analysis of the (paired)
change in IAH (Gold Score) over the 24-week duration
of the trial using the t-test without consideration of the
intervention or monitoring groups in order to evaluate
the effect of undergoing any intervention or monitoring
over the 24-week period.
Other outcomes will be assessed at baseline and
24 weeks. Analysis methods will generally be similar to
that described for the primary analysis but alternative
techniques such as McNemar’s test and logistic regres-
sion will be used as appropriate.
Further analyses will be undertaken using HbA1c and
the separate continuous glucose monitoring measures
(time spent in the following separate ranges: <2.5 mmol/l,
<3 mmol/l, <4 mmol/l, >7 mmol/l, >10 mmol/l, between 4
and 7 mmol/l and between 3 and 10 mmol/l) as outcome
variables.
Similar analyses will be undertaken on scores from all
PRO measure scores used in the study (Table 2).
A number of measures relating to SH (ADA criteria)
will be analysed: number of episodes of SH at 24 weeks,
change in SH between baseline and 24 weeks (reported
as difference in annualised rate pre and post-interven-
tion), change in SH between baseline and 24 weeks
(reported as the proportion of participants with reduc-
tion in number of SH events compared between the
timepoints) and change in proportion without SH be-
tween baseline and 24 weeks.
Changes in weight, total daily dose of insulin, and in
glucose lability will be subject to analysis in a similar
manner to the primary outcome.
Wherever possible participants who elect to withdraw
from the study will be followed up so that final outcome
data are obtained, enabling their inclusion in an Intentionto Treat (ITT) analyses. This will form the analysis groups
for the analyses described above.
Analyses restricted to those participants who were allo-
cated to use RT-CGM will be considered, in order to allow
use of the further covariate of low or high CGM use
(defined by consideration of a pre-defined cut-off value)
throughout the 24-week period. Variables analysed in this
manner will include IAH (Gold Score), episodes of SH,
HbA1c and several of the glucose monitoring measures.
Variables with missing data will be examined and the
amount of missing data described. Data analysis will take
the form of a complete case analysis, although imput-
ation of values may be considered for the primary out-
come variable alone should this be missing to a
sufficient extent.
Significance levels will be set at α=0.05 throughout.
Safety data are to be documented but will not be sub-
ject to statistical analysis.
A detailed analysis plan will be finalised prior to the
commencement of data analysis.
Data from the clamp study will be analysed separately;
however a comparison will be made between the IAH
(Gold) based definition of response and a response
measure derived from the clamp results.
Trial Governance
Trial management will be overseen by a Trial Manage-
ment Group who will meet regularly to discuss the oper-
ational aspects of the trial. An independent Data
Monitoring and Ethics Committee (DMEC) will be con-
vened to undertake independent review, monitoring safety
and efficacy endpoints. The DMEC will comprise two
physicians not connected to the trial (at least one of whom
will have expertise in hypoglycaemia), one statistician and
one patient representative. The DMEC will have full ac-
cess to unblinded study data.
A Trial Steering Committee (TSC) will supervise the
trial, ensuring it is conducted to high standards in
accordance with the protocol, the principles of GCP,
and with regard to participant safety. This committee
will have an independent chair with expertise in
hypoglycaemia. In addition to the Chief Investigator
(Professor James Shaw) and Principal Investigators, the
TSC will consist of a sponsor/funder representative,
representatives of the Newcastle Clinical Trials Unit
and two consumer representatives. The TSC will also
consider safety issues for the trial and relevant infor-
mation from other sources, ensuring at all times that
ethical considerations are met when recommending
the continuation of the trial.
Discussion
Over recent years, it has become increasingly clear that
SH is the major factor limiting the overall level of
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T1DM. We believe that this study will provide definitive
evidence that recurrent SH is preventable even in the
majority of those at highest risk. This will enable a truly
evidence-based approach to improving day-to-day dia-
betes management for all those currently living with the
risk and fear of SH. In addition, characteristics of the
minority in whom optimised conventional therapy is
likely to prove inadequate will be defined, enabling early
identification and intervention.
While the interventions in this trial are widely used
in an attempt to reduce the incidence of SH, there is
little evidence from adequately powered RCTs support-
ing their use, with most existing RCTs having been
powered for change in glycated haemoglobin rather
than SH or IAH. The primary objective of this trial is
to determine whether these treatments improve aware-
ness of hypoglycaemia and, secondarily, to determine
whether they have an impact on SH events and overall
glycaemic control. Crucially, this unique trial will also
determine the impact of these intensive interventions
on a range of patient-reported outcomes.
The trial does pose challenges, perhaps foremost the
need to ensure equal input to all study participants and
not provide additional care to those randomised to pump
therapy. The protocol was designed to take this into con-
sideration. Participants randomised to MDI will also be
provided with insulin pumps so that this group is not dis-
advantaged by not having access to a bolus calculator.
Secondly, study investigators will need to remain abso-
lutely focused on biochemical hypoglycaemia avoidance,
undiluted by attempts to tighten or maintain overall gly-
caemic control. This may be made more challenging by
existing investigator and participant behaviours. For this
reason, detailed insulin titration protocols (detailed above)
will be used across all sites.
This ambitious and intensive trial will demonstrate de-
finitively whether SH, a cause of major morbidity in up
to 5000 adults with T1DM in the UK, can be prevented
successfully in even those at highest risk by optimised
conventional management using existing technology.
Overall biomedical, psychosocial and health utility im-
pact of MDI, CSII and RT in this group will be deter-
mined employing optimised measures as detailed above.
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